(MedPage Today) — Ten-year follow-up from the randomized LIR!C trial favored ileocecal resection over infliximab (Remicade) for achieving sustained clinical remissions in patients with ileal Crohn’s disease. (Lancet Gastroenterology & Hepatology…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
